{"nctId":"NCT01312766","briefTitle":"Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients","startDateStruct":{"date":"2011-02"},"conditions":["Infertility"],"count":270,"armGroups":[{"label":"hMG-IBSA","type":"EXPERIMENTAL","interventionNames":["Drug: Menotropins"]},{"label":"Menopur","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Menotropins"]}],"interventions":[{"name":"Menotropins","otherNames":[]},{"name":"Menotropins","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women undergoing ovarian stimulation for IVF with the following characteristics:\n\n  * Able and willing to sign the Patient Consent Form and adhere to the study visitation schedule\n  * \\>18 and \\<40 years old\n  * BMI between 18 and 30 kg/m2\n  * less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery)\n  * basal FSH \\<10 IU/L and E2 \\<80 pg/ml (\\~290 pmol/l)\n  * Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination\n  * Successful down-regulation performed with a standard GnRH-Agonist long protocol (Criteria for successful down-regulation: endometrial thickness \\< 7mm or serum E2 level \\<50 pg/ml (\\~185 pmol/l).\n\nExclusion Criteria:\n\n* age \\<18 and \\>40 years\n* primary ovarian failure or women known as poor responders (i.e. requiring more than 225 IU of hMG as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with a pre-ovulatory E2 serum concentration \\<500pg/ml (\\~1800 pmol/l))\n* PCOS\n* one or both ovaries inaccessible for oocyte retrieval\n* ovarian cysts \\>10 mm\n* hydrosalpinx that have not been surgically removed or ligated;\n* stage 3 or 4 endometriosis\n* oocyte donation\n* implantation of previously frozen embryos\n* patients affected by pathologies associated with any contraindication of being pregnant\n* hypersensitivity to the study medication\n* abnormal bleeding of undetermined origin\n* uncontrolled thyroid or adrenal dysfunction\n* neoplasias\n* severe impairment of renal and/or hepatic function\n* use of concomitant medications that might interfere with study evaluations (e.g. non-study hormonal medications, prostaglandin inhibitors, psychotropic agents)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Number of Oocytes Retrieved","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"6.6"},{"groupId":"OG001","value":"9.7","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Mean hMG Dose (Total);","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2171.4","spread":"980"},{"groupId":"OG001","value":"2303.6","spread":"906"}]}]}]},{"type":"SECONDARY","title":"Embryo Quality (Percentage of Patients With at Least One Top Quality Embryo)","description":"Assessed by counting the total number of embryos obtained, the number of embryos transferred, frozen and discarded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":"1.74"},{"groupId":"OG001","value":"63.3","spread":"1.65"}]}]}]},{"type":"SECONDARY","title":"Positive b-hCG Test","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null},{"groupId":"OG001","value":"45.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Controlled Ovarian Stimulation Duration (Days)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"1.3"},{"groupId":"OG001","value":"10.6","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"17-Î² Estradiol (E2) Serum Concentration on the Monitoring Day Before hCG Injection;","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2613.8","spread":"1531.6"},{"groupId":"OG001","value":"2364.0","spread":"1441.6"}]}]}]},{"type":"SECONDARY","title":"Implantation Rate","description":"defined as the mean of the total number of implanted embryos (presence of gestational sac assessed by ultrasound) divided by the total number of transferred embryos x 100;","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":"41.0"},{"groupId":"OG001","value":"28.2","spread":"36.9"}]}]}]},{"type":"SECONDARY","title":"Clinical Pregnancy Rate,","description":"defined as a pregnancy showing ultrasound embryonic heart activity at 10 - 11 weeks after embryo transfer;","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"37.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Mature (Grade III Metaphase II) Oocytes Retrieved.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"6.0"},{"groupId":"OG001","value":"8.2","spread":"5.1"}]}]}]},{"type":"SECONDARY","title":"Ratio Mature/Total Number of Oocytes Retrieved.","description":"Percentage of retrieved oocytes considered to be mature.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Inseminated Oocytes (IVF and ICSI)","description":"number of oocytes that were inseminated via IVF or injected via ICSI technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"5.9"},{"groupId":"OG001","value":"8.4","spread":"5.0"}]}]}]},{"type":"SECONDARY","title":"Number of Cleaved Embryos","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"3.8"},{"groupId":"OG001","value":"4.8","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Live Birth Rate","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":null},{"groupId":"OG001","value":"36.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":135},"commonTop":["Headache","Abdominal distension","fatigue","Abdominal pain upper","Hot flushes"]}}}